Rani Therapeutics Holdings Inc (NASDAQ: RANI) kicked off on Monday, up 57.43% from the previous trading day, before settling in for the closing price of $2.02. Over the past 52 weeks, RANI has traded in a range of $1.82-$8.75.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 83.82% over the past five years. While this was happening, its average annual earnings per share was recorded 7.44%. With a float of $14.99 million, this company’s outstanding shares have now reached $26.04 million.
Let’s look at the performance matrix of the company that is accounted for 140 employees. In terms of profitability, gross margin is 56.07%, operating margin of -2103.53%, and the pretax margin is -2200.98%.
Rani Therapeutics Holdings Inc (RANI) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Rani Therapeutics Holdings Inc is 48.82%, while institutional ownership is 6.68%. The most recent insider transaction that took place on Nov 24 ’23, was worth 10,582,982. In this transaction 10% Owner of this company sold 5,265,165 shares at a rate of $2.01, taking the stock ownership to the 8,400 shares. Before that another transaction happened on Nov 24 ’23, when Company’s 10% Owner bought 5,265,165 for $2.01, making the entire transaction worth $10,582,982. This insider now owns 12,131,554 shares in total.
Rani Therapeutics Holdings Inc (RANI) Latest Financial update
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.36 earnings per share (EPS), higher than consensus estimate (set at -0.37) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.44% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -9.40% during the next five years compared to 0.28% growth over the previous five years of trading.
Rani Therapeutics Holdings Inc (NASDAQ: RANI) Trading Performance Indicators
Take a look at Rani Therapeutics Holdings Inc’s (RANI) current performance indicators. Last quarter, stock had a quick ratio of 1.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.18, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.03 in one year’s time.
Technical Analysis of Rani Therapeutics Holdings Inc (RANI)
Rani Therapeutics Holdings Inc (NASDAQ: RANI) saw its 5-day average volume 11.11 million, a positive change from its year-to-date volume of 0.37 million. As of the previous 9 days, the stock’s Stochastic %D was 85.21%. Additionally, its Average True Range was 0.29.
During the past 100 days, Rani Therapeutics Holdings Inc’s (RANI) raw stochastic average was set at 31.55%, which indicates a significant decrease from 88.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 205.21% in the past 14 days, which was higher than the 111.80% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.54, while its 200-day Moving Average is $3.75. Nevertheless, the first resistance level for the watch stands at $3.51 in the near term. At $3.84, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.34. If the price goes on to break the first support level at $2.68, it is likely to go to the next support level at $2.18. The third support level lies at $1.85 if the price breaches the second support level.
Rani Therapeutics Holdings Inc (NASDAQ: RANI) Key Stats
The company with the Market Capitalisation of 93.14 million has total of 50,420K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -33,970 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -6,810 K.
